Loading clinical trials...
Loading clinical trials...
Graded Strategy for Pharmacological Treatment of Heroin Dependence
The objective of this study is to compare optimally given methadone maintenance treatment (MMT) for heroin dependence with a novel, sequential strategy, where patients are offered buprenorphine as first line treatment, allowed dose adjustments as needed, and switched to methadone if the maximal dose of buprenorphine is insufficient.
The objective of this study is to compare optimally given methadone maintenance treatment (MMT) for heroin dependence with a novel, sequential strategy (STEP), where patients are offered buprenorphine as first line treatment, allowed dose adjustments as needed, and switched to methadone if the maximal dose of buprenorphine is insufficient. For this purpose, 96 subjects at two centers (Uppsala and Stockholm) are randomized to MMT or STEP and followed for 6 months. Retention in treatment is the primary outcome. Secondary outcomes in completers are proportion urine samples free of illicit opiates on app. twice weekly sampling, and problem severity as measured by a semistructured interview, the Addiction Severity Index (ASI) at baseline and after 3 and 6 months.
Age
20 - No limit years
Sex
ALL
Healthy Volunteers
No
Dept of Clinical Neuroscience, Karolinska Inst
Stockholm, Sweden
Start Date
August 1, 2005
Completion Date
March 1, 2006
Last Updated
October 24, 2006
96
Estimated participants
methadone
DRUG
buprenorphine / methadone sequence
DRUG
Relapse prevention
BEHAVIORAL
Contingency management
BEHAVIORAL
Lead Sponsor
Karolinska University Hospital
Collaborators
NCT01999946
NCT03922659
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT00249470